1
Views
0
CrossRef citations to date
0
Altmetric
Commentary

Well-Being of Obese Individuals: Therapeutic Perspectives

&
Pages 1729-1733 | Published online: 07 Dec 2010

Bibliography

  • Kaplan LM . Pharmacologic therapies for obesity.Gastroenterol. Clin. North Am.39, 69–79 (2010).
  • Bray GA . Medications for obesity: mechanisms and applications.Clin. Chest. Med.30, 525–538 (2009).
  • Muench J , HamerAM. Adverse effects of antipsychotic medications.Am. Fam. Physician81, 617–622 (2010).
  • Tremblay A , DoucetE. Obesity: a disease or a biological adaptation?Obes. Rev.1, 27–35 (2000).
  • Gilbert JA , DrapeauV, AstrupA, TremblayA. Relationship between diet-induced changes in body fat and appetite sensations in women.Appetite52, 809–812 (2009).
  • Doucet E , St-PierreS, AlmérasN, DesprésJP, BouchardC, TremblayA. Evidence for the existence of adaptive thermogenesis during weight loss.Br. J. Nutr.85, 715–723 (2001).
  • Puhl R , BrownellKD. Bias, discrimination, and obesity.Obes. Res.9, 788–805 (2001).
  • Fontaine KR . Weight loss and health-related quality of life.Am. J. Manag. Care7, 926–927 (2001).
  • Chaput JP , DrapeauV, HetheringtonM, LemieuxS, ProvencherV, TremblayA. Psychobiological impact of a progressive weight loss program in obese men.Physiol. Behav.86, 224–232 (2005).
  • Chaput JP , DrapeauV, HetheringtonM, LemieuxS, ProvencherV, TremblayA. Psychobiological effects observed in obese men experiencing body weight loss plateau.Depress. Anxiety24, 518–521 (2007).
  • Chaput JP , ArguinH, GagnonC, TremblayA. Increase in depression symptoms with weight loss: association with glucose homeostasis and thyroid function.Appl. Physiol. Nutr. Metab.33, 86–92 (2008).
  • Reynolds GP , KirkSL. Metabolic side effects of antipsychotic drug treatment – pharmacological mechanisms.Pharmacol. Ther.125, 169–179 (2010).
  • Richardson CR , FaulknerG, McDevittJ, SkrinarGS, HutchinsonDS, PietteJD. Integrating physical activity into mental health services for persons with serious mental illness.Psychiatr. Serv.56, 324–331 (2005).
  • Poulin MJ , ChaputJP, SimardVet al. Management of antipsychotic-induced weight gain: prospective naturalistic study of the effectiveness of a supervised exercise programme. Aust. NZ J. Psychiatry 41, 980–989 (2007).
  • Lawlor DA , HopkerSW. The effectiveness of exercise as an intervention in the management of depression: systematic review and meta-regression analysis of randomised controlled trials.BMJ322, 763–767 (2001).
  • Craft LL , LandersDM. The effect of exercise on clinical depression and depression resulting from mental illness: a mata-analysis.J. Sports Exerc. Psychol.20, 339–357 (1998).
  • Faulkner G , BiddleS. Exercise as an adjunct treatment for schizophrenia: a review of the literature.J. Ment. Health8, 441–457 (1999).
  • Martinsen E . The effects of exercise on mental health in clinical populations. In: European Perspectives on Exercise and Sport Psychology. Biddle S (Ed.) Human Kinetics, Stanningley, UK, 185–211 (1995).
  • Astrup A . Is cardiometabolic risk improved by weight-loss drugs?Lancet376(9741), 567–568 (2010).
  • Christensen R , KristensenPK, BartelsEM, BliddalH, AstrupA. Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials.Lancet370, 1706–1713 (2007).
  • Gadde KM , AllisonDB. Combination therapy for obesity and metabolic disease.Curr. Opin. Endocrinol. Diabetes Obes.16, 353–358 (2009).
  • Padwal R , LiSK, LauDC. Long-term pharmacotherapy for overweight and obesity: a systematic review and meta-analysis of randomized controlled trials.Int. J. Obes. Relat. Metab. Disord.27, 1437–1446 (2003).
  • Padwal R , KezouhA, LevineM, EtminanM. Long-term persistence with orlistat and sibutramine in a population-based cohort.Int. J. Obes.31, 1567–1570 (2007).
  • Foster GD , WaddenTA, VogtRA, BrewerG. What is a reasonable weight loss? Patients’ expectations and evaluations of obesity treatment outcomes.J. Consult. Clin. Psychol.65, 79–85 (1997).
  • Robinson JR , NiswenderKD. What are the risks and the benefits of current and emerging weight-loss medications?Curr. Diab. Rep.9, 368–375 (2009).
  • Greenway FL , FujiokaK, PlodkowskiRAet al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomized, double-blind, placebo-controlled, Phase 3 trial. Lancet 376(9741), 595–605 (2010).
  • Smith SR , WeissmanNJ, AndersonCMet al. Multicenter, placebo-controlled trial of lorcaserin for weight management. N. Engl. J. Med. 363, 245–256 (2010).
  • Bérubé-Parent S , Prud‘hommeD, St-PierreS, DoucetE, TremblayA. Obesity treatment with a progressive clinical tri-therapy combining sibutramine and a supervised diet-exercise intervention.Int. J. Obes.25, 1144–1153 (2001).
  • Halford JC , BoylandEJ, BlundellJE, KirkhamTC, HarroldJA. Pharmacological management of appetite expression in obesity.Nat. Rev. Endocrinol.6, 255–269 (2010).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.